Loading
EPHB2 (Ephrin type-B receptor 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Thyroid cancer and Neuroendocrine tumours.
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Functions in axon guidance during development.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes clinical 0.93, genetic literature 0.30, literature 0.97, genetic association 0.19, somatic mutation 0.72, animal model 0.43).
In plain words · EPHB2 (Ephrin type-B receptor 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Thyroid cancer and Neuroendocrine tumours.
EPHB2 (Ephrin type-B receptor 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Thyroid cancer and Neuroendocrine tumours.
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells.
No product in this corpus aims at EPHB2 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA EPHB2: RNA tissue enhanced (intestine 22 nTPM); high antibody staining in 7 normal tissues; highest cancer staining testis cancer (9 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Prostate cancer, Thyroid cancer, Neuroendocrine tumours); Open Targets associates it with 1 specific cancer type at or above 0.5 (medullary thyroid gland carcinoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas EPHB2 tissue; Open Targets ENSG00000133216 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Chan et al, Oncogene, 1991, "eek and erk, new members of the eph subclass of receptor protein-tyrosine kinases". Source.
Sources: HGNC HGNC:3393 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P29323 (protein name, function text, keywords and locations (REST API)); CIViC gene EPHB2 (2 evidence items, 0 assertions, 2 variants; diseases: Prostate Cancer (GraphQL API, CC0)); Open Targets ENSG00000133216 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: prostate cancer 0.51, thyroid cancer 0.56, neuroendocrine neoplasm 0.55 (GraphQL API, CC0))
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. In addition to axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Location: Cell membrane; Cell projection, axon; Cell projection, dendrite; Secreted (UniProt). Locus 1p36.12 (HGNC).
RNA: tissue enhanced (intestine 22 nTPM), detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Cervix, Duodenum, Endometrium, Epididymis.
RNA cancer enhanced: Colon Adenocarcinoma 75 pTPM, Rectum Adenocarcinoma 73 pTPM.
Medium only: breast cancer, glioma, head and neck cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"EPHB2" OR ABSTRACT:"EPHB2" OR TITLE:"EPH receptor B2" OR ABSTRACT:"EPH receptor B2" OR TITLE:"Ephrin type-B receptor 2" OR ABSTRACT:"Ephrin type-B receptor 2" OR TITLE:"Hek5" OR ABSTRACT:"Hek5" OR TITLE:"Tyro5" OR ABSTRACT:"Tyro5" OR TITLE:"EPHT3" OR ABSTRACT:"EPHT3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EPHB2, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.